2seventy bio, Inc. (TSVT)

NASDAQ: TSVT · IEX Real-Time Price · USD
5.35
-0.03 (-0.56%)
At close: Mar 28, 2024, 4:00 PM
5.65
+0.30 (5.61%)
After-hours: Mar 28, 2024, 7:36 PM EDT

Company Description

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.

The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.

It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2seventy bio, Inc.
2seventy bio logo
Country United States
Founded 2021
Industry Biotechnology
Sector Healthcare
Employees 274
CEO William D. Baird III, M.B.A.

Contact Details

Address:
60 Binney Street
Cambridge, Massachusetts 02210
United States
Phone 339-499-9300
Website 2seventybio.com

Stock Details

Ticker Symbol TSVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860782
CUSIP Number 901384107
ISIN Number US9013841070
Employer ID 86-3658454
SIC Code 2834

Key Executives

Name Position
Nick Leschly President and Director
Dr. Philip D. Gregory D. Phil., DPHIL Chief Scientific Officer
William D. Baird III, M.B.A. Chief Executive Officer
Vicki Eatwell Chief Financial Officer
Jessica Snow Senior Vice President of Quality and Head of Operations
Susan Abu-Absi Ph.D. Chief Technology Officer
Teresa L. Jurgensen J.D. Senior Vice President, General Counsel and Corporate Secretary
Kerri Jensen Head of People and Culture
Jenn Snyder Senior Vice President of Corporate Affairs
Dr. Steven Bernstein M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 20, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 20, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 13, 2024 8-K Current Report
Mar 7, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals